[SCHEDULE 13G/A] Abivax SA American SEC Filing

Rhea-AI Filing Summary

Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report joint beneficial ownership of 3,480,144 Abivax SA ordinary shares (represented by American Depository Shares), equal to 4.78% of the outstanding class. The filing shows 0 shares of sole voting or dispositive power and 3,480,144 shares of shared voting and dispositive power, with the percentage calculated from 72,784,660 ordinary shares outstanding per the issuer's disclosure.

The reporting persons state the securities were not acquired to change or influence control of the issuer (other than activities solely in connection with a nomination under applicable rules). The statement is filed jointly by the two Deep Track entities and David Kroin.

Positive

• Disclosed beneficial ownership: 3,480,144 shares, representing 4.78% of the class
• Transparency of control: Filing shows shared voting and dispositive power and a joint filing statement assigning amendment responsibilities

Negative

• None.

Insights

Securities Analyst

TL;DR: Joint disclosure of a 4.78% stake (3.48M shares) with shared voting power; below 5% threshold, indicating limited control impact.

The Schedule 13G/A documents that Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin collectively beneficially own 3,480,144 Abivax shares, representing 4.78% of 72,784,660 outstanding shares. The reported position carries no sole voting or dispositive power and 3,480,144 shared voting and dispositive power. The filing includes a certification that the holdings were not acquired to change or influence control, supporting a non-activist disclosure posture based on the information provided.

Corporate Governance Expert

TL;DR: Joint filing improves transparency; coordinated shareholding is recorded but the stake is under 5%, so no clear control change is indicated.

The joint filing clarifies ownership attribution among the reporting persons and documents shared voting/dispositive authority over 3,480,144 shares. The percent ownership (4.78%) is calculated from the issuer's stated outstanding share count. The document includes a certification that the securities were not acquired to alter control, and the joint filing statement assigns responsibility for future amendments among the signatories.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Abivax SA

(Name of Issuer)

Ordinary Shares (represented by American Depository Shares)

(Title of Class of Securities)

00370M103

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00370M103

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,480,144.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,480,144.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,480,144.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.78 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 00370M103

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,480,144.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,480,144.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,480,144.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.78 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 00370M103

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,480,144.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,480,144.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,480,144.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.78 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Abivax SA
(b)	Address of issuer's principal executive offices: 7-11 boulevard Haussmann, 75009 Paris, France
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Ordinary Shares (represented by American Depository Shares)
(e)	CUSIP No.: 00370M103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,480,144
(b)	Percent of class: 4.78%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,480,144
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,480,144
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	08/14/2025

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	08/14/2025

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	08/14/2025

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Ordinary Shares as of August 14, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 72,784,660 Ordinary Shares outstanding as of June 30, 2025, according to the issuer's filing with Euronext on July 17, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

How many ABVX shares do the reporting persons beneficially own?

They beneficially own 3,480,144 shares, representing 4.78% of the class (based on 72,784,660 shares outstanding).

Who filed the Schedule 13G/A for Abivax (ABVX)?

The filing was made jointly by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin.

What voting and dispositive power do the reporting persons report?

Sole voting power: 0; Shared voting power: 3,480,144; Sole dispositive power: 0; Shared dispositive power: 3,480,144.

Does the filing indicate intent to influence control of Abivax (ABVX)?

The certification in the filing states the securities were not acquired to change or influence control of the issuer (except activities solely in connection with a nomination under applicable rules).

What share count was used to calculate the ownership percentage?

The percentage is calculated from 72,784,660 ordinary shares outstanding, per the issuer's Euronext filing referenced in the exhibit.